For Immediate Release: January 13, 2015
Physician-driven Medpace Expands Global Therapeutic Leadership in Drug Development Dr. Markus Heep Joins Medpace as Medical Director for Infectious Disease
CINCINNATI, OH — (January 13, 2015) –Dr. Markus Heep, MD has joined Medpace as Medical Director for infectious disease clinical research. Medpace, a global drug and medical device Clinical Research Organization (CRO), is unique in its physician-driven approach to clinical research which gives Sponsors the advantage of early and ongoing insight and guidance from therapeutic experts throughout trial design and execution. Dr. Heep, based in Munich, Germany, joins a team of ID physicians and will extend Medpace’s ability to support global ID trials with hands-on medical leadership, collaboration and site feasibility in Europe. Dr. Heep has over 23 years of infectious diseases experience in clinical, academic and biotech industries.
About Dr. Markus Heep, MD
Markus Heep, MD is a board-certified Medical Microbiologist and an expert on bacterial and fungal infections with 10 years of clinical and academic qualifications, and 13 years of research and development leadership in international Biotech and “Big Phama” industry before joining Medpace. In the pharmaceutical industry, Dr. Heep participated as leading ID expert in essentially all procedures from phase I design to NDA submission preparation in skin and respiratory infection indications as well as candidemia and invasive aspergillosis. He also designed and managed post-approval regulatory studies.
As medical microbiologist, Dr. Heep worked at several university hospitals. He also provided diagnostic service as leader of reference laboratories for public and industry studies. He published numerous research articles mainly on antibacterial resistance markers. In addition he acquired clinical skills in Hematology and Oncology as an investigator in clinical studies.
Dr. Heep is member of the American Society for Microbiology as well as several European infectiological societies. As a medical microbiologist with a strong background in academic research and clinical infectiology, he is also experienced in profiling and candidate selection of research compounds as well as licensing activities. He has formed a solid network of experts and opinion leaders in mycology and bacterial infections.
Medpace is a global full-service clinical research organization (CRO) providing Phase I-IV core development services for drug, biologic, and device programs. Medpace has strong experience supporting development programs across a number of therapeutic and specialty areas including oncology, cardiovascular, metabolic/diabetes, infectious disease, neuroscience, gastrointestinal diseases, regenerative medicine, pediatrics, and rare disease/orphan indications. With extensive medical expertise, and renowned regulatory affairs department, Medpace employs 2000 employees and has clinical trial experience in over 45 countries and six regions – the US, Europe, Central and Eastern Europe, India, Asia Pacific, and Africa. From feasibility, research site compatibility, safety, and logistics, Medpace brings efficiencies and operational excellence to both drug and device development programs. In addition, Medpace offers integrated imaging, central and bioanalytical lab capabilities, and clinical pharmacology through wholly-owned business units to provide cohesive, streamlined, and standardized trial management.
For more information visit the Medpace website at: www.medpace.com.